Between 1988 and 1995, the first randomized controlled trial (RCT) of breast self-exam (BSE) was conducted in Shanghai, China. Subsequent policy recommendations transformed the landscape of breast cancer screening in North America as practice guidelines shifted from "BSE" toward "breast awareness." Critiques of the study raised issues of race, regionalism, and difference. I turn to Margaret Lock's concept "local biology" to tease out the complexities of these arguments, and expand upon it to consider the impact of local ecologies of screening on receipt and implementation of international behavioral clinical trial results. The case study of the Shanghai trial illuminates conflicts and controversies around what constitutes evidence in breast cancer prevention research, and for whom. [Keywords: Clinical trials, biomedicalization, breast cancer screening, China]Foreign Language Translations:Local Biologies and Ecologies of Screening: Tracing the Aftereffects of the "Shanghai Study"[Keywords: Clinical trials, biomedicalization, breast cancer screening, China]Biologias Locais e Ecologias de Rastreamento: Tracando as Sequelas do "Estudo de Xangai"[Palavras-chave: Ensaios clinicos, biomedicalizacao, rastreio do cancro da mama, China]...Local Biologies and Ecologies of Screening: Tracing the Aftereffects of the "Shanghai Study"...(ProQuest: ... denotes non-US-ASCII text omitted.)In 1993, the National Institutes of Health (NIH) passed the NIH Inclusion Act, designed to address the overwhelming reliance on white middle class men for pharmaceutical drug development by requiring the inclusion of women and ethnic minorities in all NIH-funded studies. Since then, a proliferation of research into the how, why, and why not of clinical trial participation and recruitment has led to what Steven Epstein (2008, 2009) has characterized as a new field of study-recruitment science or recruitmentology. Interest in the mechanics and mechanisms of research participation has produced a plethora of studies reporting ethnically-defined differences in attitudes toward research-including barriers such as historically-based mistrust in the healthcare system, fears of experimentation, and "mis"understandings of scientific methods such as randomization (Ford et al. 2005; Christian and Trimble 2003; Corbie-Smith, Miller, and Ransohoff2004; Cox and McGarry 2003; Noah 2003; Yancey, Ortega, and Kumanyika 2006). While this interest in the "representativeness"-in terms of ethnicity and race-of research participants is largely focused on pharmaceutical treatment trials, the underlying logic of inclusion and difference (Epstein 2009) informs responses to health behavior trials as well. This article traces responses to one such randomized controlled trial (RCT) of breast self-exam (BSE)-the largest of its kind, conducted between 1988 and 1995 in Shanghai, China-and to the policy recommendations which followed reporting of the study findings.Medical anthropologists have ethnographically explored the globalization and localization of pharmaceutical clinical trials, detailing ethical variability in the conduct of research (Petryna 2005, 2007b, 2009), professionalization of research participation (Abadie 2010, Fisher 2009), and the pharmaceuticalization of public health through trial access (Petryna 2007a; Biehl 2007, 2009). Recently, Fisher questioned the assumed and often touted low participation of ethnic minorities in clinical trials, showing instead that Black and Latino men make up the majority of participants in Phase I trials recruiting healthy volunteers, some of the riskiest trials available (Fisher and Kalbaugh 2011). This research points to the importance of differentiations between and attention to the particulars of trials (e.g., participating in a Phase I trial of a new chemotherapy agent is very different in terms of risk than participation in a Phase III study comparing two different forms of anti-depressants). …